Duloxetine for the Treatment of Generalized Anxiety Disorder

NCT00803361 ↗

Phase 3 Completed 210 enrolled Eli Lilly and Company Boehringer Ingelheim · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a 15 week study comparing how well duloxetine and placebo treatments improve generalized anxiety disorder

Timeline

Start: 2008-12
Primary completion: 2010-01
Completion: 2010-01

Outcome

Met primary endpoint

registry Duloxetine vs Placebo; p = 0.006; Mean Difference (Final Values) -1.62 (95% CI -2.76 to -0.48) NCT00803361 ↗

paper Patients treated with duloxetine had significantly greater improvement compared to placebo on the HADS-A (mean change -6.6 vs. -4.9, respectively, P = 0.022). PMID 22088518 ↗

Publications

Wu WY, Wang G, Ball SG, Desaiah D, Ang QQ. Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China. Chin Med J (Engl). 2011 Oct;124(20):3260-8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Duloxetine	Small molecule	60 mg	Oral
Subject	Duloxetine	Small molecule	120 mg	Oral